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Abstract: Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, 
strontium, parathyroid hormone, and selective estrogen receptor modulators (SERM). 
Advantages and disadvantages exist for each category as some patients may, for example, not 
tolerate bisphosphonates for gastrointestinal side effects, and especially in women in whom 
osteoporosis is frequent, several options for treatment are needed. The objectives of this 
review were to critically appraise the effects of bazedoxifene on risk of fractures especially 
in women at high risk of fractures. A systematic literature search was conducted for studies, 
especially randomized controlled trials with fractures as end-points. Bazedoxifene is a new 
member of the SERM group. The literature search identified one randomized controlled trial 
with fractures as end-point. This was a 3-year randomized double-blind placebo controlled 
trial in which 7492 postmenopausal women aged 55 to 85 years were randomly allocated to 
1) bazedoxifene (20 [n = 1886] or 40 [n = 1872] mg/day); 2) raloxifene (60 mg/day, n = 1849); 
or 3) placebo (n = 1885). The risk of vertebral fractures decreased with both 20 (HR 0.58, 95% 
CI 0.38 to 0.89) and 40 (HR 0.63, 95% CI 0.42 to 0.96) mg of bazedoxifene per day compared 
to placebo. There was no reduction in non-vertebral fractures. A subgroup of women with 
a priori high risk of fractures was identified post hoc. In this subgroup there was a reduction in 
the risk of non-vertebral fractures with the 20 mg dose of bazedoxifene compared to placebo 
(HR 0.50, 95% CI 0.28 to 0.90). In the 40 mg bazedoxifene group no significant reduction in 
non-vertebral fractures was seen in this subgroup (HR 0.70, 95% CI 0.40 to 1.20). In general 
post-hoc defined subgroup analyses should be interpreted with caution. However, the results 
indicate that bazedoxifene may be effective in preventing vertebral fractures in postmenopausal 
women with osteoporosis.
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Introduction
Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, 
strontium, parathyroid hormone, and selective estrogen receptor modulators (SERM). 
Advantages and disadvantages exist for each group as some patients may, for example, 
not tolerate bisphosphonates for gastrointestinal side effects, and especially in women 
in whom osteoporosis is frequent, several options for treatment are needed. This 
is particularly important because of the involvement of estrogen deficiency in the 
pathogenesis of osteoporosis in women. The objectives of this review were to critically 
appraise the effects of bazedoxifene on risk of fractures especially in women at high 
risk of fractures. A systematic search of the literature was conducted for studies, 
especially randomized controlled trials with fractures as end-points.International Journal of Women’s Health 2009:1 98
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The paper evaluates the effects of estrogen and the 
effects of SERM on estrogen, and the pharmacokinetics and 
pharmacodynamics of bazedoxifene and its effects on clinical 
end-points, especially fractures but also other important 
end-points linked to the estrogen system such as breast 
cancer and endometrial cancer. The literature was searched 
systematically and the effects of bazedoxifene were critically 
appraised and compared to the effects of other drugs not 
just in the SERM class of drugs but also with other classes 
of drugs against osteoporosis. The paper thus summarizes 
not just the effects from randomized controlled trials of 
bazedoxifene, but also assesses its effect in comparison with 
other drug classes. It also assesses the effects on bone mineral 
density in relation to the effects on fracture risk.
Bazedoxifene is a third-generation SERM.1 Tamoxifen 
was the first-generation, and raloxifene the second. Signifi-
cant differences have been shown between the generations 
in terms of effects especially on the uterus and the breast 
tissue.2 The SERM class of drugs are drugs with selective 
effects on the estrogen receptor. In contrast to estrogens 
and estrogen receptor agonists, these are partial agonists/
antagonists. Development of newer generations with more 
selective effects may thus prove advantageous in terms of 
effects on bone and side effects.
Estrogen effects
Estrogens have positive effects on bone by inhibiting 
osteoclastic resorption,3,4 which leads to an increase in 
bone mineral density (BMD)5 and a decrease in the risk of 
fractures.6–8 In a meta-analysis, estrogen therapy in any form 
was associated with a decrease in the risk of non-vertebral 
fractures (relative risk [RR] 0.73, 95% confidence internval 
[CI] 0.56 to 0.94)9 and vertebral fractures (RR 0.67, 95% 
CI 0.45 to 0.98).10 A subsequent large-scale randomized 
controlled trial6 has shown that estrogen plus progestogen 
were borderline significantly effective in preventing hip 
(hazard ratio [HR] 0.66, 95% CI 0.45 to 0.98) and vertebral 
fractures (HR 0.66, 95% CI 0.44 to 0.98), although this 
significance was not sustained after adjustment for con-
founders (HR 0.66, 95% CI 0.33 to 1.33 for hip fractures 
and HR 0.66, 95% CI 0.32 for 1.34 for vertebral fractures). 
For conjugated estrogens alone, a large-scale randomized 
controlled trial also showed a reduction in hip (HR 0.61, 
95% CI 0.41 to 0.91) and vertebral fractures (RR 0.62, 
95% CI 0.42 to 0.93), but again this not sustained after 
adjustment for confounders (HR 0.61, 95% CI 0.33 to 1.11 
for hip fractures, and HR 0.62, 95% CI 0.34 to 1.13 for 
vertebral fractures).8
However, estrogen and estrogen plus progestogens 
(estrogen therapy: ET or estrogen plus progestogen therapy: 
EPT) have been associated with detrimental effects in other 
organ systems. In the breast, EPT has been associated with 
an increased risk of breast cancer,6 whereas ET has not 
been associated with an increased risk of breast cancer.8 
For cardiovascular events, EPT has been associated with 
an increased risk of myocardial infarction and other cardiac 
events and an increased risk of cerebrovascular events.6 ET 
has been associated with an increased risk of stroke, but not 
cardiac events.8 ET is associated with an increased risk of 
endometrial cancer,11 but EPT has not.12 Another concern 
with ET and EPT is an increased risk of deep venous throm-
boembolism.12 Some of the differences between ET and EPT 
may be linked to the progestogen component of EPT, as the 
progestogens may possess androgen effects.
The studies mentioned above have mainly been for conju-
gated estrogens; however similar results have been reported 
for the native 17-beta-estradiol.13,14
The estrogen receptor
The estrogen receptor per se contains two subgroups: estrogen 
receptor alpha is located in the breast and endometrium, 
whereas estrogen receptor beta is located in bone, heart, 
endothelium and a number of other tissues.15 Selective actions 
against subtypes of the estrogen receptor may thus modulate 
some of the detrimental effects of estrogen and enhance the 
positive effects.
SERM
These are drugs with specific actions on subtypes of the 
estrogen receptor. They are typically agonist/antagonists of 
the estrogen receptor.
The first clinically used drug in the class was tamoxifene, 
which is in use as a drug to treat estrogen receptor positive 
breast cancer. However, tamoxifene suffers some of the same 
detrimental effects as estrogen such as endometrial cancer.16 
Tamoxifene does not seem to prevent fractures in women 
with breast cancer 17 although BMD may increase.18–20
Raloxifene was marketed as a drug to treat and prevent 
osteoporosis. It was shown to increase BMD21 and to 
reduce the risk of vertebral fractures,22–26 although the 
risk of non-vertebral fractures did not seem to decrease.27 
Raloxifene was associated with a significant decrease in 
the risk of breast cancer (estrogen receptor positive breast 
cancer).28,29 It was associated with an increased risk of deep 
venous thromboembolism22 and an increased risk of leg 
cramps.22 In older women an increased risk of fatal30 but not International Journal of Women’s Health 2009:1 99
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non-fatal strokes has been reported. Raloxifene does not seem 
to significantly affect the rate of cardiovascular events30,31 
although serum cholesterol levels may decrease.21 Raloxifene 
is associated with an increased risk of vasomotor symptoms 
such as hot flushes.22 Raloxifene does not seem to stimulate 
the endometrium21 although more episodes of endometrial 
cavity fluid have been reported.22
Other SERMs include lasofofoxifene,32,33 toremifene, 
idoxifene, arzoxifene, acolbifene and bazedoxifene along 
with a number of other compounds.34 For most of these only 
few clinical data are available.
Fracture risk
The major determinants of fracture risk are age and gender.35 
Other major determinants include reduced bone mineral 
density,36 prior fractures,37 corticosteroid use,38,39 smoking,40,41 
alcohol intake,42 and a number of other factors such as 
low body weight,43 reduced eye sight,44 reduced physical 
performance,44 and use of psychotropic drugs.45–47
Special scores have been constructed to identify women 
at high risk of fractures using clinical risk factors48 in 
addition to low BMD. This is particularly important as it 
may be more difficult to show significant fracture risk reduc-
tions in randomized controlled trials in women at low risk 
(say, with low BMD but no prior fractures equivalent to a 
secondary preventive scenario) than in women at high risk of 
fractures (women with, say, a prior spine fracture – a tertiary 
preventive scenario).49
A special algorithm, the FRAX algorithm48 has been 
constructed to predict expected 10-year risk of fractures (hip 
or major osteoporotic fractures) based on age (only valid in the 
range 40 to 90 years), gender, weight, height, prior fracture, 
parental fracture history, current smoking, glucocorticoid 
use, rheumatoid arthritis, secondary osteoporosis, alcohol 
intake, and femoral neck BMD.
Bazedoxifene
Methods
The effects of bazedoxifene were reviewed using a systematic 
search of Pubmed, Embase, and Web of Science on June 19, 
2009, using the term ‘bazedoxifene’. This produced a total of 
213 unique references (46 from Pubmed, 148 from Embase, 
and 120 from Web of Science).
Pharmacokinetics
Bazedoxifene is rapidly absorbed50 with a tmax of approxi-
mately 2 hours and exhibits a linear increase in plasma 
concentrations for single doses from 0.5 mg up to 120 mg. 
Following intravenous administration of a 3 mg dose of 
bazedoxifene, the volume of distribution is 14.7 ± 3.9 L/kg. 
Bazedoxifene is highly bound (95.8% to 99.3%) to plasma 
proteins in vitro. Bazedoxifene is extensively metabolized 
in women. Glucuronidation is the major metabolic pathway. 
Little or no cytochrome P450-mediated metabolism is 
evident. Bazedoxifene-5-glucuronide is the major circu-
lating metabolite. The concentrations of this glucuronide 
are approximately 10-fold higher than those of unchanged 
active substance in plasma. Bazedoxifene is eliminated with 
a half-life of approximately 30 hours. Steady-state con-
centrations are achieved by the second week of once-daily 
administration. The apparent oral clearance of bazedoxifene 
is approximately 4 to 5 L/h/kg. The major route of excretion 
of radio-labeled bazedoxifene is the feces, and less than 1% 
of the dose is eliminated in urine.32
Pharmacodynamics
The SERMs differ significantly in terms of tissue specificity.51 
Bazedoxifene seems to have less effect on the uterus than 
estradiol and raloxifene in animal experiments52 due to 
lower estrogen receptor alpha agonistic effects.53 In a study 
on rats52 the uterine weight differed significantly betweem 
bazedoxifene 0.5 mg/kg (mean ± SEM: 32.7 ± 2.40, 135% of 
control weight), raloxifene 0.5 mg/kg (45.0 ± 1.23 mg, 185% 
of control weight), and conjugated estrogens (98.7 ± 6.30 mg, 
406% of control weight). In human studies bazedoxifene was 
associated with a decreased thickness of the endometrium at 
doses of 30 to 40 mg/day compared to placebo or conjugated 
estrogen plus medroxyprogesterone (mean ± SEM increase: 
0.04 ± 0.12 mm for 30 mg, 0.12 ± 0.11 mm for 40 mg, 
0.58 ± 0.21 mm for placebo, and 1.60 ± 0.23 mm for 
conjugated estrogen plus medroxyprogesterone acetate after 
168 days).54 This is in contrast to effects of other SERMs 
such as tamoxifen16 and raloxifene.22 In the mammary 
gland in animals bazedoxifene was more antagonistic to 
conjugated estrogens than raloxifene and lasofofoxifene.53 
Bazedoxifene thus has more more tissue-specific effects 
than other SERMs.
effects on BMD
In a 2-year, randomized, placebo-controlled, double-blind 
trial 1434 postmenopausal women (45 years and 1 year 
postmenopausal) were randomly allocated in a dose-dependent 
manner to bazedoxifene (10 [n = 321], 20 [n = 322] or 
40 mg/day [n = 319]), raloxifene (60 mg/day, n = 311) 
or placebo (n = 310).55 The inclusion criteria were: 
1) osteopenia (lumbar spine or femoral neck T-score International Journal of Women’s Health 2009:1 100
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between –1 and –2.5); or 2) clinical risk factors for osteoporosis 
(family history of fracture, bilateral oophorectomy, current 
smoking, weight 58 kg, inadequate calcium intake, or 
low physical activity).55 Bazedoxifene was significantly 
more efficient in increasing BMD than placebo and was 
equally effective as raloxifene in increasing BMD. There 
was no significant trend with bazedoxifene dose and BMD.55 
However, at 12 to 24 months bazedoxifene 20 to 40 mg was 
more efficient in increasing hip BMD than 10 to 20 mg.55 
The patients in this study on bazedoxifene and BMD were in 
general at low risk of fractures,55 as they were only osteopenic 
and had additional risk factors which did not place them at 
high risk of fractures.
BMD was unchanged at 24 months compared to baseline 
with bazedoxifene in contrast to a decline with placebo,55 
in contrast to other drugs against osteoporosis, which sig-
nificantly increase BMD in the range of 3% in the femoral 
neck and 6.5% in the lumbar spine with alendronate after 
24 months.56 The difference in BMD at 24 months of  around 
1.5% between bazedoxifene and placebo (around 0.1 Z-scores) 
would translate into a fracture risk reduction of 1.5–0.1 = 0.95 
(5%) for overall fracture risk and 2.3–0.1 = 0.90 (10%) for spine 
fractures using the risk estimates of Marshall et al.36
effects on fracture risk
In a 3-year, randomized, double-blind, placebo-controlled 
trial 7492 postmenopausal (2 years after last menstruation) 
women aged 55 to 85 years were randomly allocated to 1) baze-
doxifene (20 [n = 1886] or 40 [n = 1872] mg/day), 2) raloxifene 
(60 mg/day, n = 1849), or 3) placebo (n = 1885).57 The inclu-
sion criteria were: 1) 1 radiologically confirmed spine 
fracture (20% compression) and lumbar spine and femoral 
neck T-scores –4; or 2) in the absence of vertebral fractures 
lumbar spine or femoral neck T-scores should be between –2.5 
and –4.57 Overall, around two thirds of the included patients 
completed the trial.57
The risk of vertebral fractures decreased with both 20 (HR 
0.58, 95% CI 0.38 to 0.89) and 40 (HR 0.63, 95% CI 0.42 to 
0.96) mg of bazedoxifene per day compared to placebo.57 The 
reduction was in the same range as with raloxifene 60 mg 
(HR 0.58, 95% CI 0.38 to 0.89).57 There was no reduction 
in the risk of non-vertebral fractures.57
A subgroup of women with a priori high risk of fractures 
was identified post-hoc. This group had femoral neck T-score 
(–3.0 or lower) and/or the presence of at least one moderate or 
severe vertebral fracture or multiple mild vertebral fractures 
at baseline, resultin in a subgroup of 1772 women. Restricting 
the analysis to a post-hoc analysis of these 1772 women with 
high risk of fractures showed a 50% reduction in the risk of 
non-vertebral fractures with the 20 mg dose of bazedoxifene 
compared to placebo (HR 0.50, 95% CI 0.28 to 0.90).57 In the 
40 mg bazedoxifene group no significant reduction in non-
vertebral fractures were seen in this subgroup of women at 
high risk of fractures (HR 0.70, 95% CI 0.40 to 1.20).57 In the 
20 mg bazedoxifene group at high risk of fractures (n = 1772) 
the risk of non-vertebral fractures was borderline significantly 
lower than with raloxifene (HR 0.56, 95% CI 0.31 to 1.01). 
Also in the 40 mg bazedoxifene group a non-significant trend 
towards a decrease in non-vertebral fractures compared to 
raloxifene was seen (HR 0.78, 95% CI 0.45 to 1.35).57
At 3 years the absolute risk of morphometric fractures was 
4.1 with placebo, 2.3% with 20 mg of bazedoxifene, and 2.5% 
with 40 mg bazedoxifene.57 This yields numbers needed to treat 
of 56 for 20 mg of bazedoxifene and 63 for 40 mg of bazedoxi-
fene for morphometric vertebral fractures, ie, 56 and 63 women 
have to be treated for 3 years to prevent one morphometric 
vertebral fracture.57 For non-vertebral fractures the correspond-
ing numbers needed to treat were 167 for 20 of bazedoxifene and 
143 for 40 mg of bazedoxifene (6.3% cumulated risk of non-
vertebral fractures after 3 years vs 5.7 and 5.6% respectively).57 
In the high risk group the number needed to treat was 24 and 
38 respectively with 20 and 40 mg of  bazedoxifene.57 The latter 
lower number reflects a 3-year cumulated risk of non-vertebral 
fractures of 9.1% in the placebo group vs 4.9% and 6.5% with 
20 and 40 mg of bazedoxifene, respectively, ie, a much higher 
absolute risk of fractures.57 This also reflects that it is much easier 
to obtain statistical significance with a high absolute fracture risk 
than with a low risk of fractures.57 When small differences in 
absolute risk are converted to compute the numbers needed to 
treat, seemingly large differences in number are not significant 
owing to wide confidence intervals because small differences 
may convert into large numbers.
Kanis et al58 re-analyzed the data from the study by 
Silverman et al.57 Kanis et al did a post-hoc analysis based 
on the 10-year modeled risk of major osteoporotic fractures 
using the FRAX algorithm as co-variate. At a modeled 
10-year risk of major osteoporotic fractures above 16%, baze-
doxifene was associated with a significant decrease in both 
morphometric vertebral and clinical fractures.58 At a 10-year 
risk of morphometric vertebral of 22%, the hazard ratio for 
morphometric vertebral fractures was 0.49, 95% CI 0.31 to 
0.79 for bazedoxifene vs placebo and for clincial fractures 
the hazard ratio was 0.68, 95% CI 0.49 to 0.93.58
The patients in this trial were thus at significantly higher 
risk of fractures than the above mentioned trial with BMD 
as end-point.55International Journal of Women’s Health 2009:1 101
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Adverse effects
In the study by Miller et al,55 deep venous thromboembolism 
was rare with bazedoxifene (0% to 0.6% with various doses 
after 2 years) and in the same range as placebo (0.3%). Leg 
cramps were in the same range as with raloxifene and as with 
placebo.55 Hot flushes were in the same range as raloxifene, but 
a little higher than with placebo.55 In the study by Silverman 
et al57 leg cramps (10.9% to 11.7% with various doses after 
3 years) and deep venous thromboembolism (0.4% to 0.5% 
with various doses after 3 years) were significantly more fre-
quent with bazedoxifene than with placebo (8.2 for leg cramps 
and 0.2% for deep venous thromboembolism), while breast 
cyst/fibrocystic breast disease was significantly less frequent.
Extensive monitoring of has cardiovascular side effects 
been performed, and no difference between bazedoxifene 
and placebo were observed for myocardial infarction, 
strokes (ischemic or hemorraghic strokes), or retinal vein 
thrombosis.55,57 This is particularly interesting given the 
tissue-specific actions of the various estrogen receptors.
Combinations of bazedoxifene  
and conjugated estrogens
In general SERMs have been shown to have weaker action 
on BMD than conjugated estrogen or 17-beta-estradiol.59 
This has led to examination of combinations of bazedoxi-
fene and estrogen. However, at present no definite data on 
BMD in humans are available. In animals the combination 
of bazedoxifene and conjugated estrogen showed that with 
bazedoxifene 3 mg/kg an increase in bone density similar to 
that for conjugated estrogen 2.5 to 5 mg/kg, but higher than 
that for 0.5 to 1 mg/kg.60 The combination of bazedoxifene 
3 mg/kg and conjugated estrogen in all doses showed an 
increase in bone density.60 However, the increase at the doses 
of 3 mg/kg of bazedoxifene and 2.5 to 5 mg/kg of conjugated 
estrogen was a little less than with conjugated estrogen alone, 
although the difference was not statistically significant.60 
Bazedoxifene plus conjugated estrogen in animals seems to 
counter some of the detrimental effects seen in humans.53,54,60 
However, more human data are needed.
Other drugs against osteoporosis
In accordance with the results for bazedoxifene,57 raloxifene 
has also been shown to reduce only vertebral but not non-
vertebral fractures in the intention-to-treat analysis in random-
ized controlled trials.22–26 In contrast, the bisphosphonates 
alendronate,56,61 risedronate,62,63 and zoledronate64 have been 
shown to reduce both vertebral and non-vertebral fracture risk 
in randomized controlled trials. For the other bisphosphonates, 
etidronate,65 ibandronate,66 pamidronate,67,68 and clodronate,69 
randomized controlled trials have demonstrated effect only 
on vertebral fractures. Strontium ranelate has demonstrated 
effects on vertebral70 and non-vertebral fractures.71 The 
parathyroid hormone teriparatide has been shown to reduce 
vertebral and non-vertebral fracture risk.72 However, for 
recombinant 1-84-PTH only a reduction in vertebral and not 
non-vertebral fractures has been demonstrated.73,74
Comments
Bazedoxifene has shown effects on the risk of vertebral but 
not non-vertebral fracture risk in the intention-to-treat analysis 
in randomized controlled trials, in line with the results for 
raloxifene.57 In post-hoc analyses, high risk groups have 
shown a decrease in non-vertebral fracture risk. However, 
post-hoc subgroup analyses have been discredited in prior 
recommendations.75 It is recommended that any subgroup anal-
yses should be preplanned to avoid searching for significant 
results.75 Although subgroup analyses may help to generate 
hypotheses and explore data, they should be performed and 
interpreted with caution and should not be used as definite 
evidence for an effect. By analyzing data in subgroups ran-
domization is usually discouraged, and the analyses are to be 
graded as cohort studies in terms of level of evidence unless 
the randomization is stratified on the subgroups.
At present the evidence supports an effect of bazo-
doxifene on vertebral fractures in postmenopausal women, 
whereas further studies are needed to establish if an effect 
on non-vertebral fractures is present in high risk subgroups. 
The effect of bazedoxifene on the skeleton is thus in line 
with the effect of raloxifene, and bazedoxifene may be used 
on the same indications as raloxifene. The value of baze-
doxifene may lie in a different risk profile than raloxifene, 
especially in terms of uterine safety, and bazedoxifene may 
thus offer an alternative for prevention and treatment of 
osteoporosis in some groups of women.
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